Josipa Flam

ORCID: 0000-0003-1351-7511
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Advanced Breast Cancer Therapies
  • PI3K/AKT/mTOR signaling in cancer
  • Oral health in cancer treatment
  • Metastasis and carcinoma case studies
  • Cancer Treatment and Pharmacology
  • Esophageal Cancer Research and Treatment
  • Multiple and Secondary Primary Cancers
  • Spaceflight effects on biology
  • Colorectal Cancer Screening and Detection
  • Oral Health Pathology and Treatment
  • Colorectal Cancer Treatments and Studies
  • Multiple Myeloma Research and Treatments
  • Estrogen and related hormone effects
  • Cancer Risks and Factors
  • Infrared Thermography in Medicine
  • Infective Endocarditis Diagnosis and Management
  • Radiation Therapy and Dosimetry
  • Soft tissue tumors and treatment
  • Colorectal and Anal Carcinomas
  • Global Cancer Incidence and Screening
  • Fungal Infections and Studies
  • Sarcoma Diagnosis and Treatment
  • Advanced Drug Delivery Systems
  • COVID-19 and healthcare impacts

University of Osijek
2017-2025

Klinički bolnički centar Osijek
2018-2021

University Hospital Centre Zagreb
2021

Indiana University School of Medicine
2017

Our objective was to assess the effects of COVID-19 antiepidemic measures and subsequent changes in function health care system on number newly diagnosed breast cancers Republic Croatia.We performed a retrospective, population- registry-based study during 2020. The comparator patients with cancer 2017, 2018, 2019. outcome change cases.The average monthly percent after initial lockdown were introduced -11.0% (95% confidence interval - 22.0% 1.5%), resulting 24% reduction cases Croatia April,...

10.1002/onco.13791 article EN other-oa The Oncologist 2021-04-16

Radioactivity is a process in which the nuclei of unstable atoms spontaneously decay, producing other and releasing energy form ionizing radiation alpha (α) beta (β) particles as well emission gamma (γ) electromagnetic waves. People may be exposed to various forms, casualties nuclear accidents, workers power plants, or while working using different sources medicine health care. Acute syndrome (ARS) occurs subjects very high dose short period time. Each has unique pathophysiological effect....

10.3390/medicina60040653 article EN cc-by Medicina 2024-04-18

Alpelisib and fulvestrant combination has improved outcomes in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-)- advanced breast cancer (BC) who relapsed or progressed on prior endocrine therapy. Hyperglycemia, target toxicity, is a frequent adverse event occurring over 60% of patients. The ITACA trial explores whether low carbohydrate dietary...

10.1093/oncolo/oyaf023 article EN cc-by The Oncologist 2025-03-01

High stroma proportion appears to be a very important prognostic factor in esophageal and breast cancer.Previous researches have shown that it might similar eff ect on colorectal cancer.Th e aim of this study was determine whether tumor infl uenced patient survival.Th is retrospective included 236 patients with cancer having undergone surgery 2006 2007 at Osijek University Hospital Center.Location the highest site deepest invasion determined.Patients were divided into groups high (>50%) low...

10.20471/acc.2017.56.01.11 article EN cc-by-nc-nd Acta Clinica Croatica 2017-01-01

e12512 Background: Disease recurrence of early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast tumor subtype is particularly challenging to manage due its complex and very heterogeneous biological nature. Namely, primary secondary resistance, one-quarter patients with disease will present the recurrence. This variability in timing highlights need better identify key biomarkers that could predict therapeutic outcomes guide personalized...

10.1200/jco.2024.42.16_suppl.e12512 article EN Journal of Clinical Oncology 2024-06-01

Disease recurrence in patients with the early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast tumor subtype is particularly challenging to manage due its complex and very heterogeneous biological nature. Namely, primary secondary resistance, one-quarter of early-stage disease will experience recurrence. This variability timing highlights need better identify key biomarkers that could predict therapeutic outcomes guide personalized treatment...

10.1155/2024/5648845 article EN cc-by The Breast Journal 2024-01-01

Penile cancer is a rare but aggressive tumor, most commonly squamous cell carcinoma. Treatment modalities depend on the stage of disease, backbone treatment surgical resection primary tumor and regional lymph nodes with use neoadjuvant/adjuvant chemotherapy radiotherapy. Our case report about 59-year-old patient which was presented bilateral inguinal lymphadenitis, scrotal penile edema. A biopsy change in penis confirmed Partial amputation an excisional performed, metastasis to nodes....

10.20471/lo.2022.50.02-03.23 article EN cc-by-nc-nd Libri Oncologici Croatian Journal of Oncology 2022-12-22

In the Conclusions of this Article, point 3, on page 46 reads: There is a difference in total five year survival rate according to cancer localization, and 72% patients with left colon comparison 62% right cancer.Point 3 has been corrected to: cancer.

10.20471/lo.2020.48.01.07 article EN cc-by-nc-nd Libri Oncologici Croatian Journal of Oncology 2020-07-07

Adenocarcinoma of the gastroesophageal junction (GEJ) and gastric cancer have poor outcomes in most patients.Perioperative chemotherapy became a standard care for resectable adenocarcinoma upper GI tract based on results MAGIC trial.The study includes patients with Stage II or III stomach, GEJ, lower esophagus.The ACCORD trial essentially supported study.Both studies showed that preoperative could induce downstaging enhance possibility potentially curative R0 resection, thus increasing...

10.20471/lo.2021.49.02-03.14 article EN cc-by-nc-nd Libri Oncologici Croatian Journal of Oncology 2021-12-22

Immune checkpoint inhibitors, such as CTLA-4 inhibitors (ipilimumab), PD-1 (nivolumab, pembrolizumab), and PD-L1 (atezolizumab, durvalumab) have become standard in the treatment of numerous malignant tumors.Immunotherapy blocks body's natural protective measures with immune inhibitors.It prevents over-activation, but it can also affect normal tissue, cause autoimmune side effects.They cover a diverse spectrum events require different approaches.Immune-related effects any organ or most...

10.20471/lo.2021.49.02-03.17 article EN cc-by-nc-nd Libri Oncologici Croatian Journal of Oncology 2021-12-22
Coming Soon ...